Encompass Health Co. (NYSE:EHC) Given Average Rating of “Buy” by Analysts

Encompass Health Co. (NYSE:EHC) has received an average rating of “Buy” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $107.11.

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Royal Bank of Canada upped their price objective on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Truist Financial reissued a “buy” rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Finally, KeyCorp upped their price target on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a report on Tuesday, October 29th.

Institutional Investors Weigh In On Encompass Health

Large investors have recently made changes to their positions in the company. TD Private Client Wealth LLC boosted its holdings in shares of Encompass Health by 2,870.0% in the third quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company’s stock worth $709,000 after buying an additional 7,089 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Encompass Health by 532.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock worth $4,860,000 after acquiring an additional 42,338 shares during the last quarter. Pathstone Holdings LLC grew its position in shares of Encompass Health by 54.5% during the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock valued at $2,032,000 after acquiring an additional 7,412 shares during the period. Deerfield Management Company L.P. Series C bought a new position in Encompass Health in the 2nd quarter worth $541,000. Finally, Meeder Asset Management Inc. lifted its position in Encompass Health by 43.8% during the third quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company’s stock valued at $6,417,000 after purchasing an additional 20,242 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Price Performance

EHC stock opened at $95.65 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The firm has a market capitalization of $9.64 billion, a price-to-earnings ratio of 23.10, a PEG ratio of 1.13 and a beta of 0.89. The firm has a 50 day moving average price of $96.74 and a 200-day moving average price of $94.28. Encompass Health has a 52-week low of $69.95 and a 52-week high of $104.55.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business earned $0.86 earnings per share. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. Equities research analysts forecast that Encompass Health will post 4.29 EPS for the current fiscal year.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.